Storia in 4 fonti

SK Biopharm strikes $800m deal for epilepsy drug from Biohaven

SK Biopharmaceuticals is staking nearly $800 million on rights to an epilepsy treatment from US biotech firm Biohaven, the company said Wednesday. In a regulato

Raccontata da

Confronto fonti

4 prospettive sulla stessa storia

AI · summaries

koreaherald.comStai leggendo4 g fa

SK Biopharm strikes $800m deal for epilepsy drug from Biohaven

SK Biopharmaceuticals is staking nearly $800 million on rights to an epilepsy treatment from US biotech firm Biohaven, the company said Wednesday. In a regulato

originale

Timeline cronologica

mercoledì 26 agosto 2026·biopharmadive.com
Biohaven trades cash for ‘upside’ with $795M epilepsy drug deal
Faced with a dwindling bank account after a series of research setbacks, Biohaven is letting go of its most advanced experimental drug in a deal one analyst viewed as a…
mercoledì 26 agosto 2026·koreaherald.com
SK Biopharm strikes $800m deal for epilepsy drug from Biohaven
SK Biopharmaceuticals is staking nearly $800 million on rights to an epilepsy treatment from US biotech firm Biohaven, the company said Wednesday. In a regulato

SK Biopharm strikes $800m deal for epilepsy drug from Biohaven

Confronto fonti

SK Biopharm strikes $800m deal for epilepsy drug from Biohaven

Timeline cronologica

Biohaven trades cash for ‘upside’ with $795M epilepsy drug deal

SK Biopharm strikes $800m deal for epilepsy drug from Biohaven

Biohaven strikes $795M deal for commercial partner in epilepsy

Biohaven and SK Biopharmaceuticals Enter into Strategic Global Licensing Agreement for Novel Kv7 Ion Channel…

Biohaven trades cash for ‘upside’ with $795M epilepsy drug deal

Biohaven and SK Biopharmaceuticals Enter into Strategic Global Licensing Agreement for Novel Kv7 Ion Channel Platform and Opakalim, Lead…

SK Biopharmaceuticals to In-License Epilepsy Drug Candidate 'Opakalim'

Biohaven strikes $795M deal for commercial partner in epilepsy